Differences in the overall direction and dynamics for both vWF:Ag and ADAMTS-13 during the course of chemotherapy at baseline and postchemotherapy (delta value) can also illustrate the “risk” of developing DVT by dividing patients according to the ratio of vWF:Ag/ADAMTS-13 at the end of the observation period. This evidence concerns the gene ADAMTS13 and deep vein thrombosis.